Another example of cross-resistance and epigenetic-mediated resistance has been shown by Burr and colleagues in a study of three lung adenocarcinoma tumours displaying a neuroendocrine transformation to small cell lung cancer under EGFR inhibition treatment with Erlotinib (a tyrosine kinase inhibitor). The gene discussed is EGFR; the disease is neoplasm.